Although PD-L1 expression, tumor mutational burden, and CD8+ tumor-infiltrating lymphocytes have been recognized as prognostic factors for ICI therapy, several studies on metastatic ccRCC have demonstrated conflicting results [2,3,4,5]. The gene discussed is CD8A; the disease is neoplasm.